Perceptive Advisors LLC grew its holdings in enGene Holdings Inc. (NASDAQ:ENGN – Free Report) by 179.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,869,076 shares of the company’s stock after buying an additional 3,771,840 shares during the period. Perceptive Advisors LLC owned 0.09% of enGene worth $52,998,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also modified their holdings of the company. Privium Fund Management B.V. acquired a new stake in shares of enGene in the fourth quarter valued at about $3,179,000. Braidwell LP acquired a new stake in shares of enGene in the third quarter valued at about $15,479,000. Omega Fund Management LLC raised its position in shares of enGene by 66.5% in the fourth quarter. Omega Fund Management LLC now owns 876,357 shares of the company’s stock valued at $7,914,000 after buying an additional 350,000 shares during the last quarter. Eventide Asset Management LLC acquired a new stake in shares of enGene in the fourth quarter valued at about $8,578,000. Finally, Cormorant Asset Management LP raised its position in shares of enGene by 72.1% in the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after buying an additional 1,676,405 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on ENGN. Piper Sandler cut shares of enGene from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $7.00 to $4.00 in a research report on Friday, May 8th. Raymond James Financial cut shares of enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 price objective for the company. in a research report on Friday, May 8th. Oppenheimer cut shares of enGene from an “outperform” rating to a “market perform” rating in a research report on Friday, May 8th. WBB Securities began coverage on shares of enGene in a research report on Monday, April 13th. They set a “buy” rating and a $21.50 price objective for the company. Finally, Wall Street Zen cut shares of enGene from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Four investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, enGene has an average rating of “Hold” and an average price target of $11.05.
enGene Price Performance
enGene stock opened at $1.74 on Thursday. enGene Holdings Inc. has a 12-month low of $1.40 and a 12-month high of $12.25. The stock has a market cap of $116.56 million, a P/E ratio of -0.80 and a beta of -0.30. The company has a 50-day moving average price of $4.10 and a 200 day moving average price of $7.10. The company has a current ratio of 12.57, a quick ratio of 11.75 and a debt-to-equity ratio of 0.10.
enGene (NASDAQ:ENGN – Get Free Report) last released its quarterly earnings data on Monday, June 15th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.91. During the same quarter last year, the firm earned $0.51 EPS. Sell-side analysts anticipate that enGene Holdings Inc. will post -1.97 earnings per share for the current year.
enGene Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Further Reading
- Five stocks we like better than enGene
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding ENGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for enGene Holdings Inc. (NASDAQ:ENGN – Free Report).
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
